Skip to content

Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy

Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00524797
Enrollment
50
Registered
2007-09-05
Start date
2007-09-30
Completion date
Unknown
Last updated
2007-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelosuppression

Keywords

Myelosuppression,, chemotherapeutic agents,, leucopenia,, thrombocytopenia,, Profonycia

Brief summary

Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. Death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs) are widely used in the treatment of chemotherapy induced neutropenia. The same Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments are expensive and have several side effects. In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life. The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia. This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.

Interventions

DIETARY_SUPPLEMENTProfonycia

Sponsors

Ziv Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients 18 years old or elder receiving chemotherapy 1/2-3 weeks

Exclusion criteria

Patients below 18 years old

Countries

Israel

Contacts

Primary ContactZidan Jamal, Prof
+972 4 6828951

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026